The State of Outsourced Mammalian and Microbial Capacity

BDO’s bioTRAK database, which tracks supply and demand for biopharmaceutical manufacturing capacity, is showing that outsourcing in the industry isn’t going away anytime soon.

BioProcess International’s Dan Stanton sat down with Dawn Ecker, Managing Director of bioTRAK Database Services at BDO, to understand what this means for the future of the biopharmaceutical industry. Read his article to dive deeper into manufacturing trends and the impact they will have on the life sciences industry.

Article originally published in BioProcess International.

Related Resources

Article

Biotechs Take a Cautious Step Back into the Market

April 25, 2024
Article

Biotechs Take a Cautious Step Back into the Market

April 25, 2024

Post-pandemic economic conditions have left biotech initial public offering (IPO) activity in the lurch, but there are signs of a return, with eight IPOs in the first quarter of 2024 alone compared to 19 in the whole of 2023.

Read More

Article

Benefits of Using Real-Time In-Process Data in Mammalian Cell Culture

April 5, 2024
Article

Benefits of Using Real-Time In-Process Data in Mammalian Cell Culture

April 5, 2024

Learn how real-time monitoring of key data in mammalian cell-based protein therapeutics production can refine your control strategy and prevent expensive setbacks.

Read More

Article

USTR Seeking Comments on Supply Chain Resilience

April 3, 2024
Article

USTR Seeking Comments on Supply Chain Resilience

April 3, 2024

On March 7, 2024, the Office of the United States Trade Representative (USTR) announced a notice in the Federal Register seeking comments to “inform the development of trade and investment policy initiatives that promote supply chain resilience.” A public hearing will follow.

Read More

Article

District Court Allows Whistleblower’s Customs Fraud Suit to Proceed

February 23, 2024
Article

District Court Allows Whistleblower’s Customs Fraud Suit to Proceed

February 23, 2024

The U.S. District Court for the Southern District of New York on January 26, 2024, declined to dismiss a False Claims Act (FCA) civil lawsuit filed by a whistleblower, which alleges that their employer misclassified imported footwear to avoid customs duties and that they were constructively discharged in retaliation for objecting to the employer’s illegal practices.

Read More